Page last updated: 2024-09-03
bq 610 and 6-ketoprostaglandin f1 alpha
bq 610 has been researched along with 6-ketoprostaglandin f1 alpha in 1 studies
Compound Research Comparison
Studies (bq 610) | Trials (bq 610) | Recent Studies (post-2010) (bq 610) | Studies (6-ketoprostaglandin f1 alpha) | Trials (6-ketoprostaglandin f1 alpha) | Recent Studies (post-2010) (6-ketoprostaglandin f1 alpha) |
---|---|---|---|---|---|
124 | 1 | 3 | 4,832 | 294 | 150 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Busija, DW; Miller, AW; Puskar, M; Tulbert, C | 1 |
Other Studies
1 other study(ies) available for bq 610 and 6-ketoprostaglandin f1 alpha
Article | Year |
---|---|
Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelins; Glyburide; In Vitro Techniques; Indomethacin; Insulin; Insulin Resistance; Male; Mesenteric Artery, Superior; Oligopeptides; Potassium Chloride; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Vasodilation | 2002 |